Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐
stages of OC are linked with high morbidity and low survival rates despite the immense …

The accumulation of tumor infiltrating lymphocytes (TILs) in ovarian cancer is prognostic for
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

The first clinically approved engineered chimeric antigen receptor (CAR) T cell therapies are
remarkably effective in a subset of hematological malignancies with few therapeutic options …

Due to the overexpression or amplification of human epidermal growth factor receptor 2
(HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on …

Immunotherapy as a treatment for cancer is a growing field of endeavor but reports of
success have been limited for epithelial ovarian cancer. Overcoming the challenges to …

Spatial heterogeneity of transcriptional and genetic markers between physically isolated
biopsies of a single tumor poses major barriers to the identification of biomarkers and the …

New approaches to cancer immunotherapy have been developed, showing the ability to
harness the immune system to treat and eliminate cancer. For many solid tumors, therapy …

Engineering T cells with chimeric antigen receptors (CARs) is an effective method for
directing T cells to attack tumors, but may cause adverse side effects such as the potentially …

The diverse repertoires of cellular mechanisms that progress certain cancer types are being
uncovered by recent research and leading to more effective treatment options. Ovarian …